The transient receptor potential channel, subfamily V, member 6 (TRPV6), is strongly expressed in advanced prostate cancer and significantly correlates with the Gleason >7 grading, being undetectable in healthy and benign prostate tissues. However, the role of TRPV6 as a highly Ca 2 þ -selective channel in prostate carcinogenesis remains poorly understood. Here, we report that TRPV6 is directly involved in the control of prostate cancer cell (LNCaP cell line) proliferation by decreasing: (i) proliferation rate; (ii) cell accumulation in the S-phase of cell cycle and (iii) proliferating cell nuclear antigen (PCNA) expression. We demonstrate that the Ca 2 þ uptake into LNCaP cells is mediated by TRPV6, with the subsequent downstream activation of the nuclear factor of activated T-cell transcription factor (NFAT). TRPV6-mediated Ca 2 þ entry is also involved in apoptosis resistance of LNCaP cells. Our results suggest that TRPV6 expression in LNCaP cells is regulated by androgen receptor, however, in a ligand-independent manner. We conclude that the upregulation of TRPV6 Ca 2 þ channel in prostate cancer cells may represent a mechanism for maintaining a higher proliferation rate, increasing cell survival and apoptosis resistance as well.
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It has been previously suggested that intracellular calcium is a second messenger playing a major role in the control of cell proliferation, differentiation and apoptosis. Indeed, alterations in Ca 2 þ homeostasis increase proliferation (Legrand et al., 2001; Thebault et al., 2006) , as well as induce differentiation (Vanoverberghe et al., 2004) and apoptosis (Skryma et al., 2000; Vanden Abeele et al., 2002 . According to a growing number of articles, cationic channels of the TRP (transient receptor potential) family are key players in calcium homeostasis and cell physiopathology (Montell et al., 2002) . In recent years, TRPV6 (TRP, Vanilloid member 6), a highly Ca 2 þ -selective channel, has emerged as a promising prognosis marker. TRPV6 is strongly expressed in advanced prostate cancer and significantly correlates with the Gleason >7 grading, making it a strong marker of tumor progression and subsequent invasion into healthy tissues (Fixemer et al., 2003; Wissenbach et al., 2004) . Previous studies have shown that TRPV6 is involved in highly calcium-selective currents in prostate cells, and that it is tightly regulated by intracellular Ca 2 þ concentrations ([Ca 2 þ ] i ) (Schindl et al., 2002; Bodding and Flockerzi, 2004; Vanden Abeele et al., 2004) . However, the precise role of Ca 2 þ entry via TRPV6 in prostate physiopathology remains illusive. Furthermore, reports on its regulation by androgen are contradictory (Peng et al., 2001) .
We initially studied TRPV6 protein expression in the LNCaP human prostate cancer cell line. Figure 1a shows detection of the expected 84 kDa TRPV6 protein. TRPV6 expression level decreased significantly after 4 days small interfering RNA (siRNA) transfection. In order to study the relative contribution of TRPV6, as a highly Ca 2 þ -selective channel, to Ca (Figure 1b) . siRNA-TRPV6 knockdown decreased the (Schwarz et al., 2006) . It was, therefore, interesting to study the potential involvement of TRPV6 in LNCaP cell growth in greater depth. The number of viable proliferating cells, measured by (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) (MTS) assay, decreased significantly following TRPV6 knockdown from day 2 to 4 after transfection (D0) (Figure 1c ). siRNA against AR, known to be crucial for prostate growth and development (Burnstein, 2005) , was used as a positive control. We also performed a cell-cycle assay with propidium iodide staining to clarify TRPV6 knockdown effects on the cell-cycle phase distribution of LNCaP cells ( Figure 1d ). Indeed, siRNA-TRPV6 decreased the number of cells entering the S-phase (siRNA-AR, used as positive control, evoked the same decrease). To demonstrate the specificity of the studied effects ascribed to TRPV6, we performed the silencing of the other TRP channel in the plasma membrane, TRPC3, which had no significant effects on both cell proliferation and cell cycle ( Figures 1c, d and f). Also, we monitored the protein level of proliferating cell nuclear antigen (PCNA). Figure 1e shows one order decrease in PCNA level following siRNA-TRPV6 treatment, being almost undetectable in siRNA-AR-treated cells. It was previously shown that human primary prostate cancer epithelial cell proliferation was promoted by store-independent Ca 2 þ entry and subsequent activation of nuclear factor of activated T-cell (NFAT) transcription factor (Thebault et al., 2006) . Interestingly, co-transfecting LNCaP cells with siRNA-TRPV6 and pNFAT-Luciferase plasmid revealed that TRPV6-induced Ca 2 þ entry contributed considerably to activating the promoter of Ca 2 þ -dependent NFAT transcription factor (Figure 1g ), known to be involved in Ca 2 þ -dependent cell proliferation (Lipskaia and Lompre, 2004) . Thus, TRPV6 is most probably involved in LNCaP cell proliferation by mediating Ca 2 þ entry, followed by the activation of Ca 2 þ -dependent NFAT transcription factor-mediated signaling pathways.
It is also well established that [Ca 2 þ ] i increase favors cell proliferation, whereas sustained [Ca 2 þ ] i increase, with the subsequent mitochondrial overload, has proapoptotic potential (for review see: Prevarskaya et al., 2004) . In this study, we investigated whether Ca 2 þ entry via TRPV6 was proapoptotic or antiapoptotic in cancer cells. A cell-cycle assay measured the number of apoptotic cells as a subG 1 population. siRNA-TRPV6 pretreatment significantly increased the number of apoptotic cells (B15%) as compared with B35% induced by siRNA-AR (Figure 1f) . Thus, our data indicate that TRPV6 expression promotes apoptosis resistance in the LNCaP cell line.
Therefore, Ca 2 þ entry via TRPV6 may not only be a mechanism for maintaining a high proliferation rate but also for increasing cell survival and inducing apoptosis resistance.
As, on the one hand, TRPV6 has previously been shown to be overexpressed in high-grade prostate cancer (Fixemer et al., 2003; Wissenbach et al., 2004) , and on the other hand, prostate cancer development is Figure 1 Ca 2 þ via TRPV6 is involved in LNCaP cell proliferation. (a) A representative western blot of TRPV6 was performed on LNCaP cells as compared to b-actin. LNCaP cells were lysed and the lysates were centrifuged at 15 000 g and 41C for 20 min, mixed with Laemmli buffer and boiled at 951C for 5 min. Total protein samples were subjected to 8% SDS-PAGE and transferred to a nitrocellulose membrane by semi-dry Western blotting (Bio-Rad Laboratories, Marnes-La-Coquette, France). The membrane was probed using rabbit polyclonal anti-TRPV6 (Alomone Labs Ltd, Jerusalem, Israel, 1/200) and anti-b-actin (Lab Vision Co., Fremont, CA, USA, 1/1000) antibodies followed by secondary antibodies. The bands on the membrane were displayed using enhanced chemiluminescence method (Pierce Biotechnologies Inc., Rockford, IL, USA). Densitometric analysis was performed using a Bio-Rad image acquisition system (Bio-Rad Laboratories). . Asterisks denote statistical significance as compared to control cells; *Po0.05, **Po0.01; n ¼ 3. (e) A western blot of PCNA. The membrane was probed using mouse monoclonal anti-PCNA (Santa-Cruz, 1/1000) and anti-bactin (Lab Vision Co., 1/1000) antibodies, followed by secondary antibodies; n ¼ 3. (f) An apoptosis assay carried out by flow cytometry, as described above, on a subG 1 population of LNCaP cells. Asterisks denote statistical significance; *Po0.01 vs control, **Po0.01 vs siTRPV6 treatment; n ¼ 3. (g) Ca 2 þ entry via TRPV6 is involved in the activation of Ca 2 þ -dependent transcriptional factor, NFAT. Cells were co-transfected with a functional noncoding siRNA#1 and pNFAT-Luciferase vector (Promega), pNFATLuciferase vector and siTRPV6 and siAR, respectively. In addition, all the cells were pre-transfected with b-galactosidase reporter vector (Promega) to normalize the results. The comparative histogram shows the effects of TRPV6 on NFAT signaling; *Po0.01 vs control (CT) þ vector; n ¼ 3. AR, androgen receptor; NFAT, nuclear factor of activated T-cell; PCNA, proliferating cell nuclear antigen; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; TRPV6, transient receptor potential channel, subfamily V, member 6.
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V Lehen'kyi et al androgen dependent (Burnstein, 2005) , we investigated whether trpv6 gene regulation was under AR control. Three approaches were used to study TRPV6 regulation by androgen in the LNCaP human cancerous androgenresponsive cell line: (i) siRNA-AR, (ii) AR-selective ligand dihydrotestosterone (DHT, 1 nM) and (iii) ARselective antagonist Casodex (10 mM). These approaches were previously used to demonstrate a direct positive regulation by AR of TRPM8, another channel in the TRP family (Bidaux et al., 2005) . In this study, AR knockdown by 200 nM siRNA significantly decreased TRPV6 mRNA after 48 h and protein levels 72 h after transfection (Figures 2a and b) . These data were confirmed by immunocytochemistry (Figure 2h ). In the series of Ca 2 þ imaging experiments, we studied whether Ca 2 þ uptake into LNCaP cell was affected by siRNA Figure 2 For figure caption see next page.
Role of TRPV6 in prostate cancer V Lehen'kyi et al against AR. Figure 2c shows that Ca 2 þ uptake is substantially suppressed upon AR knockdown. In these experiments, the amplitude of the global response, but not the initial rate of Ca 2 þ increase, has been affected by siRNA-AR treatment, suggesting that some other (AR independent) proteins could be involved in the first phase of the response to the 'Ca 2 þ add back' assay. Thus, the results suggest that AR regulates the TRPV6 expression and/or activity. To elucidate the nature of this regulation, LNCaP cells grown in 2% serum-supplied Rosewell Park Memorial Institute (RPMI) medium were treated with either 1 nM DHT AR-selective agonist or 10 mM Casodex-selective antagonist for 24 h (Figure 2d ). Both DHT and Casodex had no significant effect on TRPV6 mRNA expression (Figure 2e ). DHT/Casodex effects were already studied in the context of androgen regulation of TRPV6 (Peng et al., 2001; Bodding et al., 2003; Vanden Abeele et al., 2003) . We believe that these variations in TRPV6 expression were too weak (for example, 0.6-and 1.5-fold changes upon DHT/Casodex treatments, respectively; Peng et al., 2001) to suggest any ligand dependency of AR regulation of trpv6 gene as compared to known androgen regulation of other TRP channel, for example, TRPM8 in LNCaP (five-to six-fold increase upon DHT treatment; Bidaux et al., 2005) . The absence of consistency/reproducibility in agonist/antagonist treatments had led us to check whether the functional blockade of AR affected TRPV6 protein expression. Thus, androgen deprivation for 6 days was used. In LNCaP cells, this treatment led to only a 1.8-fold increase in TRPV6 protein expression levels. These variations in both TRPV6 and AR protein levels are presented in Figure 2f . Taking the role of AR in differentiation of LNCaP cells upon androgen deprivation (Vanoverberghe et al., 2004) , it is likely that AR preserves its functionality. The addition of 1 nM DHT to LNCaP cells deprived of steroids for 6 days did not lead to any significant change in either TRPV6 or AR mRNA expression levels (Figure 2g ). The fact that the functional status of AR, that is, transcriptional activity, strongly correlates with its phosphorylation status other than activation by androgens, has already been considered for the treatment of prostate cancer (Wang et al., 1999) . Increasing evidence indicates that androgens may also have an indirect influence on the expression of genes that do not contain ARresponsive elements, by modulating the activity of other transcription factors, mediating growth factor expression in paracrine or autocrine mode, or inducing changes in the production of other hormones (Korkmaz et al., 2002; Xiao et al., 2005) . We chose another steroid receptor, vitamin D 3 receptor (VDR), as a positive model of TRPV6 regulation, since trpv6 has already been identified as a VDR-regulated gene (Wang et al., 2005) . Unlike DHT, 1,25-dihydroxyvitamin D3 increased TRPV6 mRNA expression in a steroid containing RPMI medium in a dose-dependent manner (Figure 2i ). Taken together, these data on trpv6 gene regulation suggest that trpv6 is not a direct ARresponsive gene, however, the presence of AR is needed in this cell type to maintain the expression of TRPV6. We conclude that TRPV6 is regulated by AR in ligandindependent manner and probably constitutes an essential cofactor of trpv6 gene transcription in prostate cancer cells.
In summary, this research demonstrated for the first time that Ca 2 þ entry via TRPV6 controlled proliferation directly and promoted apoptosis resistance in prostate cancer cells. In view of strong correlation of TRPV6 with the Gleason >7 tumor grading in prostate cancer, this channel is a promising therapeutic target for the development of new treatments. . Cells grown on glass coverslips were fixed in 3.5% paraformaldehyde in phosphate-buffered saline (PBS), then washed in PBS and stained with both rabbit polyclonal anti-TRPV6 antibody (Alomone Labs Ltd., 1/200) and mouse monoclonal anti-AR (Neomarkers, 1/500). Alexa Fluor 546 goat anti-rabbit IgG (Molecular Probes, Cergy Pontoise, France, 1/4000) was used as a secondary antibody for TRPV6 staining and Alexa Fluor s 488 donkey anti-mouse IgG (Molecular Probes, 1/4000) for AR staining. Fluorescence analysis was carried out using a Carl Zeiss Laser Scanning Systems LSM 510 connected to a Zeiss Axiovert 200M with 63 Â 1.4 numerical aperture oil immersion lens at room temperature, and data were processed using Carl Zeiss LSM Image Examiner software. (i) Effects of 100 nM 1,25-dihydroxyvitamin D3 on TRPV6 mRNA level in LNCaP cells. PCR: total RNA was isolated using the guanidium thiocyanate-phenol-chloroform extraction procedure, reverse transcribed using moloney murine leukemia (MuLV) reverse transcriptase (Perkin Elmer, Courtaboeuf, France). The following primers were used for PCR: TRPV6 (NM_018646), F1: ATGGTGATGCGGCTCATCAGTG; B1: GTAGAAGTGGCCTAGCTCCTCG; AR (NM_000044), F1: TGTCCATCTTGT CGTCTTCG; B1: CTGGAGTTGACATTGGTGAAGG; PSA (NM_001648), F1: CTCACCCTGTCCGTGACGTGGATT; B1: AAGCTGTGGCTGACCTGAAATA; b-actin (NM_001101), F1: CAGAGCAAGAGAGGCATCCT; B1: GTTGAAGGTCTC AAACATGATC. DNA amplification procedure included an initial 5 min denaturation step at 951C, and 33 cycles of 30 s at 951C, 30 s at 591C, 30 s at 721C, and finally 7 min at 721C. All experiments were performed at least three times, unless otherwise stated. Both PCR and western blotting bands were quantified using densitometric analysis option in the Bio-Rad image acquisition system (Bio-Rad Laboratories). See Figure 1 for western blotting specifications. AR, androgen receptor; Csdx, Casodex; DHT, dihydrotestosterone; PBS, phosphate-buffered saline; SD, steroid deprivation; TRPV6, transient receptor potential channel, subfamily V, member 6.
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